Roseburia intestinalis inhibits oncostatin M and maintains tight junction integrity in a murine model of acute experimental colitis

Scandinavian Journal of Gastroenterology

Volumn 54, Issue 4, 2019, Pages 432-440

  Tan, Bei ^a,b   Luo, Weiwei ^a,b   Shen, Zhaohua ^a,b   Xiao, Mengwei ^a,b   Wu, Shuai ^a,b   Meng, Xiangrui ^a,b   Wu, Xing ^a,b   Yang, Zhenyu ^a,b   Tian, Li ^a,b   Wang, Xiaoyan ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Key Laboratory of Nonresolving Inflammation and Cancer   (China)

Author keywords

anti TNF therapy; colitis; Microbiota; oncostatin M; tight junction

Indexed keywords

CLAUDIN 1; OCCLUDIN; ONCOSTATIN M; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR; DEXTRAN SULFATE; TLR5 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CACO-2 CELL LINE; COLON; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEXTRAN SULFATE SODIUM-INDUCED COLITIS; DISEASE ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; ROSEBURIA INTESTINALIS; TIGHT JUNCTION; ANIMAL; C57BL MOUSE; CLOSTRIDIALES; COLITIS; DISEASE MODEL; FEMALE; GENETICS; INTESTINE MUCOSA; KNOCKOUT MOUSE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CACO-2 CELLS; CLOSTRIDIALES; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ONCOSTATIN M; TIGHT JUNCTIONS; TOLL-LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85063896373     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365521.2019.1595708     Document Type: Article

References (32)

1. Kamm MA. Rapid changes in epidemiology of inflammatory bowel disease. Lancet. 2017;390:2741–2742.
2. Hirano A, Umeno J, Okamoto Y, et al. Comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis. J Gastroenterol Hepatol. 2018;33:1590–1597.
3. Pascal V, Pozuelo M, Borruel N, et al. A microbial signature for Crohn's disease. Gut. 2017;66:813–822.
4. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–1283.
5. Imhann F, Vich Vila A, Bonder M, et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut. 2018;67:108–119.
6. Duncan SH, Hold GL, Barcenilla A, et al. Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int J Syst Evol Microbiol. 2002;52:1615–1620.
7. Shen Z, Zhu C, Quan Y, et al. Insights into Roseburia intestinalis which alleviates experimental colitis pathology by inducing anti-inflammatory responses. J Gastroenterol Hepatol. 2018;33(10):1751–1760.
8. Zhu C, Song K, Shen Z, et al. Roseburia intestinalis inhibits interleukin17 excretion and promotes regulatory T cells differentiation in colitis. Mol Med Rep. 2018;17:7567–7574.
9. Chelakkot C, Ghim J, Ryu S. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50:103.
10. Holmberg FEO, Pedersen J, Jørgensen P, et al. Intestinal barrier integrity and inflammatory bowel disease: stem cell-based approaches to regenerate the barrier. J Tissue Eng Regen Med. 2018;12:923–935.
11. Li H, Gong Y, Xie Y, et al. Clostridium butyricum protects the epithelial barrier by maintaining tight junction protein expression and regulating microflora in a murine model of dextran sodium sulfate-induced colitis. Scand J Gastroenterol. 2018;53(9):1031–1042.
12. Simeoli R, Mattace Raso G, Lama A, et al. Preventive and therapeutic effects of Lactobacillus paracasei B21060-based synbiotic treatment on gut inflammation and barrier integrity in colitic mice. J Nutr. 2015;145:1202–1210.
13. Bron P, Kleerebezem M, Brummer R, et al. Can probiotics modulate human disease by impacting intestinal barrier function? Br J Nutr. 2017;117:93–107.
14. Hermanns H. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 2015;26:545–558.
15. West NR, Owens BMJ, Hegazy AN. The oncostatin M-stromal cell axis in health and disease. Scand J Immunol. 2018;88:e12694.
16. West N, Hegazy A, Owens B, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23:579–589.
17. Kolho K-L, Korpela K, Jaakkola T, et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol. 2015;110:921.
18. Magnusson MK, Strid H, Sapnara M, et al. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis. 2016;10:943–952.
19. Zhou Y, Xu Z, He Y, et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems. 2018;3(1):e00188–17.
20. Neurath M. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269–278.
21. Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38:127–142.
22. Wirtz S, Popp V, Kindermann M, et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12:1295.
23. Na YR, Hong JH, Lee MY, et al. Proteomic analysis reveals distinct metabolic differences between granulocyte-macrophage colony stimulating factor (GM-CSF) and macrophage colony stimulating factor (M-CSF) grown macrophages derived from murine bone marrow cells. Mol Cell Proteomics. 2015;14:2722.
24. Mukai K, Miyagi T, Nishio K, et al. S100A8 production in CXCR2-expressing CD11b + Gr-1 high cells aggravates hepatitis in mice fed a high-fat and high-cholesterol diet. J Immunol. 2016;196:395–406.
25. Pothoven K, Norton J, Hulse K, et al. Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol. 2015;136:737–746.e4.
26. Takata F, Sumi N, Nishioku T, et al. Oncostatin M induces functional and structural impairment of blood-brain barriers comprised of rat brain capillary endothelial cells. Neurosci Lett. 2008;441:163–166.
27. Pothoven K, Schleimer R. The barrier hypothesis and Oncostatin M: restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease. Tissue Barriers. 2017;5:e1341367.
28. de Souza H, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:739–749.
29. Gren S, Grip O. Role of monocytes and intestinal macrophages in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2016;22:1992–1998.
30. Hidalgo-Garcia L, Galvez J, Rodriguez-Cabezas M, et al. Can a conversation between mesenchymal stromal cells and macrophages solve the crisis in the inflamed intestine? Front Pharmacol. 2018;9:179.
31. Kühl AA, Erben U, Kredel LI, et al. Diversity of intestinal macrophages in inflammatory bowel diseases. Front Immunol. 2015;6:613.
32. Beigel F, Friedrich M, Probst C, et al. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members. PLoS One. 2014;9:e93498.